Calculation of the cut-off and evaluation of the dynamics of natriuretic peptide for optimization the management of comorbid patients with thyrototoxicosis and heart failure
Objective: to determine the cut-off of natriuretic peptide for optimization dyagnosis heart failure in comorbid patients with thyrotoxicosis, to assess the dynamics of this indicator during therapy.Materials and methods: 111 patients (58,3±5,6 years) were divided into 4 groups. Te main group consiste...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
State Budget Educational Institute of Higher Professional Education, Rostov State Medical University, Ministry Health of Russian Federation
2018-12-01
|
| Series: | Медицинский вестник Юга России |
| Subjects: | |
| Online Access: | https://www.medicalherald.ru/jour/article/view/697 |
| _version_ | 1811179424457949184 |
|---|---|
| author | E. V. Pashchenko A. I. Chesnikova V. I. Kudinov V. P. Terentyev O. E. Kolomatskaya |
| author_facet | E. V. Pashchenko A. I. Chesnikova V. I. Kudinov V. P. Terentyev O. E. Kolomatskaya |
| author_sort | E. V. Pashchenko |
| collection | DOAJ |
| description | Objective: to determine the cut-off of natriuretic peptide for optimization dyagnosis heart failure in comorbid patients with thyrotoxicosis, to assess the dynamics of this indicator during therapy.Materials and methods: 111 patients (58,3±5,6 years) were divided into 4 groups. Te main group consisted of 25 patients with CHD, CHF II-III FC and thyrotoxicosis; the 1st group of comparison - 30 patients with CHD and CHF II-III FC, without thyrotoxicosis; the 2nd group — 30 patients with thyrotoxicosis without CHD, the 3rd group - 26 patients with thyrotoxicosis and CHD, with no signs of CHF. Te fnding of thyroid gland, the level of NT-proBNP was estimated at baseline and afer 6 months therapy. A new cut-off NT-proBNP for the diagnosis of CHF in comorbid patients was calculated by using ROC analysis.Results: the high concentration of NT-proBNP was detected in all patients (more then 125 pg/ml), in the 2nd comparison group — 225.5 (180.1, 376.1) pg/ml. Te NT-proBNP values in the patients of the 1st and 3rd comparison groups did not differ signifcantly. Te highest level of NT-proBNP was detected in the main group — 712.1 (434.3, 893.9) pg/ml. A cut-off of this marker for screening CHF in comorbid patients with CHD and thyrotoxicosis was calculated - 556.4 pg/ml (a sensitivity of 72 %, a specifcity of 100 %, an accuracy of 87.2 % (p <0.001)). Afer 6 months therapy in the 2nd comparison group the level of NT-proBNP decreased by 74 % (р<0,0001) and has reached the normal value (64,6 (42,2;76,3)); in the main group the level decreased by 43% and was 406,7 (309,1; 498,6) pg/ml.Conclusions: the patients of all groups showed an increased concentration of NT-proBNP. Te highest level of NT-proBNP was observed in the group of patients with CHF by CHD and thyrotoxicosis. Te level of NT-proBNP was determined - 556.4 pg/ml, which allows us to diagnose CHF in patients with a combination of CHD and thyrotoxicosis. |
| first_indexed | 2024-04-11T06:35:25Z |
| format | Article |
| id | doaj.art-df455ef30349481bbca42da119d3503a |
| institution | Directory Open Access Journal |
| issn | 2219-8075 2618-7876 |
| language | English |
| last_indexed | 2024-04-11T06:35:25Z |
| publishDate | 2018-12-01 |
| publisher | State Budget Educational Institute of Higher Professional Education, Rostov State Medical University, Ministry Health of Russian Federation |
| record_format | Article |
| series | Медицинский вестник Юга России |
| spelling | doaj.art-df455ef30349481bbca42da119d3503a2022-12-22T04:39:51ZengState Budget Educational Institute of Higher Professional Education, Rostov State Medical University, Ministry Health of Russian FederationМедицинский вестник Юга России2219-80752618-78762018-12-0194738010.21886/2219-8075-2018-9-4-73-80459Calculation of the cut-off and evaluation of the dynamics of natriuretic peptide for optimization the management of comorbid patients with thyrototoxicosis and heart failureE. V. Pashchenko0A. I. Chesnikova1V. I. Kudinov2V. P. Terentyev3O. E. Kolomatskaya4Rostov Regional Clinical Hospital, Rostov-on-DonRostov State Medical University, Rostov-on-DonRostov State Medical University, Rostov-on-DonRostov State Medical University, Rostov-on-DonRostov State Medical University, Rostov-on-DonObjective: to determine the cut-off of natriuretic peptide for optimization dyagnosis heart failure in comorbid patients with thyrotoxicosis, to assess the dynamics of this indicator during therapy.Materials and methods: 111 patients (58,3±5,6 years) were divided into 4 groups. Te main group consisted of 25 patients with CHD, CHF II-III FC and thyrotoxicosis; the 1st group of comparison - 30 patients with CHD and CHF II-III FC, without thyrotoxicosis; the 2nd group — 30 patients with thyrotoxicosis without CHD, the 3rd group - 26 patients with thyrotoxicosis and CHD, with no signs of CHF. Te fnding of thyroid gland, the level of NT-proBNP was estimated at baseline and afer 6 months therapy. A new cut-off NT-proBNP for the diagnosis of CHF in comorbid patients was calculated by using ROC analysis.Results: the high concentration of NT-proBNP was detected in all patients (more then 125 pg/ml), in the 2nd comparison group — 225.5 (180.1, 376.1) pg/ml. Te NT-proBNP values in the patients of the 1st and 3rd comparison groups did not differ signifcantly. Te highest level of NT-proBNP was detected in the main group — 712.1 (434.3, 893.9) pg/ml. A cut-off of this marker for screening CHF in comorbid patients with CHD and thyrotoxicosis was calculated - 556.4 pg/ml (a sensitivity of 72 %, a specifcity of 100 %, an accuracy of 87.2 % (p <0.001)). Afer 6 months therapy in the 2nd comparison group the level of NT-proBNP decreased by 74 % (р<0,0001) and has reached the normal value (64,6 (42,2;76,3)); in the main group the level decreased by 43% and was 406,7 (309,1; 498,6) pg/ml.Conclusions: the patients of all groups showed an increased concentration of NT-proBNP. Te highest level of NT-proBNP was observed in the group of patients with CHF by CHD and thyrotoxicosis. Te level of NT-proBNP was determined - 556.4 pg/ml, which allows us to diagnose CHF in patients with a combination of CHD and thyrotoxicosis.https://www.medicalherald.ru/jour/article/view/697natriuretic peptide, chronic heart failure, comorbid patients, coronary heart desease, thyrotoxicosis, cut-off |
| spellingShingle | E. V. Pashchenko A. I. Chesnikova V. I. Kudinov V. P. Terentyev O. E. Kolomatskaya Calculation of the cut-off and evaluation of the dynamics of natriuretic peptide for optimization the management of comorbid patients with thyrototoxicosis and heart failure Медицинский вестник Юга России natriuretic peptide, chronic heart failure, comorbid patients, coronary heart desease, thyrotoxicosis, cut-off |
| title | Calculation of the cut-off and evaluation of the dynamics of natriuretic peptide for optimization the management of comorbid patients with thyrototoxicosis and heart failure |
| title_full | Calculation of the cut-off and evaluation of the dynamics of natriuretic peptide for optimization the management of comorbid patients with thyrototoxicosis and heart failure |
| title_fullStr | Calculation of the cut-off and evaluation of the dynamics of natriuretic peptide for optimization the management of comorbid patients with thyrototoxicosis and heart failure |
| title_full_unstemmed | Calculation of the cut-off and evaluation of the dynamics of natriuretic peptide for optimization the management of comorbid patients with thyrototoxicosis and heart failure |
| title_short | Calculation of the cut-off and evaluation of the dynamics of natriuretic peptide for optimization the management of comorbid patients with thyrototoxicosis and heart failure |
| title_sort | calculation of the cut off and evaluation of the dynamics of natriuretic peptide for optimization the management of comorbid patients with thyrototoxicosis and heart failure |
| topic | natriuretic peptide, chronic heart failure, comorbid patients, coronary heart desease, thyrotoxicosis, cut-off |
| url | https://www.medicalherald.ru/jour/article/view/697 |
| work_keys_str_mv | AT evpashchenko calculationofthecutoffandevaluationofthedynamicsofnatriureticpeptideforoptimizationthemanagementofcomorbidpatientswiththyrototoxicosisandheartfailure AT aichesnikova calculationofthecutoffandevaluationofthedynamicsofnatriureticpeptideforoptimizationthemanagementofcomorbidpatientswiththyrototoxicosisandheartfailure AT vikudinov calculationofthecutoffandevaluationofthedynamicsofnatriureticpeptideforoptimizationthemanagementofcomorbidpatientswiththyrototoxicosisandheartfailure AT vpterentyev calculationofthecutoffandevaluationofthedynamicsofnatriureticpeptideforoptimizationthemanagementofcomorbidpatientswiththyrototoxicosisandheartfailure AT oekolomatskaya calculationofthecutoffandevaluationofthedynamicsofnatriureticpeptideforoptimizationthemanagementofcomorbidpatientswiththyrototoxicosisandheartfailure |